KD Pharmaceutical Enterprise Under The Assetlight Operation Mode The Financial

In recent years,health issues have become a growing public concern,and the demand for pharmaceutical products has increased,and the country is also introducing pharmaceutical policies to promote the development of the industry.With the change of national policy and the adjustment of market environment,the business environment of pharmaceutical enterprises has also changed.The traditional profit model has been difficult to adapt to the needs of the market,and the assetlight operation model,as a new business model,has attracted much attention from pharmaceutical companies.However,the advantages and impacts of the asset-light operation model have not been fully studied and elucidated.Therefore,this study selects the KD pharmaceutical enterprise as the research object and explores the impact of the asset-light operation model on the financial performance of pharmaceutical enterprises,aiming to select an appropriate business model for pharmaceutical enterprises to improve their financial performance and promote their sustainable development.The case chosen for this paper is KD Pharmaceutical Enterprise,a pharmaceutical company that entered the CRO pharmaceutical industry early and introduced the asset-light operation in China,whose asset-light operation model is very representative.This paper introduces the basic situation of KD Pharmaceutical Enterprise and combines qualitative and quantitative methods to explore the characteristics of KD Pharmaceutical Enterprise’s asset-light operation model.It is found that the light assets of KD Pharmaceuticals mainly include R&D innovations and brand assets,while the financial characteristics are characterized by more current assets,less fixed assets and less current liabilities.By analyzing the financial characteristics of KD Pharmaceuticals under its light asset operating model in the four dimensions of solvency,profitability,operating capacity and cash flow,and selecting 74 pharmaceutical companies based on a factor analysis to horizontally evaluate their financial performance for five years from 2017 to 2021,as well as conducting our own vertical evaluation through a financial strategy matrix analysis,it was found that KD Pharmaceuticals in its light asset operating model The overall performance of KD Pharmaceuticals under its asset light operating model is good,but there are still some problems.In conclusion,we propose specific countermeasures to help KD Pharma improve its financial performance going forward.The conclusions of this paper are as follows: from an overall perspective,the adoption of the asset-light operation model is suitable for KD Pharmaceuticals;its financial performance is generally good,but there is still room for improvement;as an explorer of the asset-light operation model,KD Pharmaceuticals’ model innovation is worthy of reference by other pharmaceutical companies.Finally,we hope that the research of this paper will provide some reference and inspiration for other pharmaceutical companies implementing the asset-light operation model,promote the better development of the pharmaceutical industry,and to a certain extent,further enrich the theoretical research on the asset-light operation model.